drugset / Trial / NCT07663032
A Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GSK Vaccines Institute for Global Health (GVGH) Quadrivalent Pan-Salmonella Vaccine With and Without Alum in Healthy Young Adults
RandomizedSequentialTriple-blindPrevention
Summary
The current clinical study will evaluate the GVGH Quadrivalent Pan-Salmonella vaccine for the first time in healthy adults in Africa. The purpose of the current Phase 1 study is to evaluate the safety, reactogenicity, and the immune response induced by the Pan-Salmonella vaccine.
Timeline
- Start
- 2026-06-24
- Primary completion
- 2027-11-14
- Completion
- 2027-11-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pan-Salmonella-with-Alum | Unknown | — | — |
| Subject | Pan-Salmonella-without-Alum | Vaccine | — | — |
| Comparator | TYPHIBEV | Vaccine | — | — |